In previous studies to determine whether chronic opiate administration might negatively feedback upon endogenous opioid systems in the CNS, investigators found no changes in steady-state concentrations of opioid peptides following morphine pelleting. However, since only steady-state levels were measured, it was still not clear whether morphine treatment altered the release and/or biosynthesis of opioid-containing neurons. The goal of the present study was to assess the effects of chronic morphine pelleting on the dynamics of fl-endorphin (fiE) biosynthesis in rats. Hence, at several times during a 7-day morphine treatment, concentrations of total flE-immunoreactivity (-it), as well as chromatographically sieved forms of fiE, were determined by RIA, and mRNA levels of pro-opiomelanocortin (POMC) were measured by a solution phase protection assay using a mouse or rat POMC 32p-labelled riboprobe. Concentrations of total flE-ir or different forms of flE-ir peptides (i.e. fl-lipotropin, flE1_31 , or flEl_27/flEl_26 ) in the hypothalamus or midbrain following either 1 or 7 days of treatment were similar in morphine-and placebo-pelleted animals. However, a significant increase in total hypothalamic flE-ir was observed following 3 days of morphine pelleting; chromatographic analyses indicated that this was primarily due to a selective increase in the opiate inactive forms of fiE, i.e. flEl_27/flEl_26. After 7 days of pelleting, morphine-treated animals tended to have lower POMC mRNA levels than those of placebo controls (20 to 50% decrease in different studies). The accumulation of hypothalamic flE-ir at 3 days, and the apparent decline in POMC mRNA levels at 7 days, lend support to the hypothesis that morphine negatively feeds back upon POMC neurons in the brain by inhibiting fiE release and biosynthesis.
INTRODUCTION
Over the past 15 years, investigators have pondered whether the tolerance and/or dependence induced by chronic opiate administration might be related to alterations in endogenous opioid systems in the brain. Shortly after the discovery of the enkephalins, Kosterlitz and Hughes 2t hypothesized that chronic morphine treatment might result in agonist-induced feedback inhibition of endogenous opioid biosynthesis, a phenomenom well established in catecholamine systems 3°'31. Early studies designed to test this hypothesis found no changes in the immunoreactive concentrations of fl-endorphin (fiE) or the enkephalins following a short-term (3-10 days) morphine treatment which produces morphine tolerance and dependence 9'13 '15,36 . However, these data were based solely upon steady-state peptide levels and provided no information about the 'turnover rate' of the endogenous opioids. Some measure of the relative rates of peptide synthesis, release, and degradation is essential to discriminate between systems which have increased, or decreased, rates of both biosynthesis and release from those which have maintained established metabolic rates, since all 3 conditions could result in similar steady-state levels of peptide product. Thanks to the large increase in our understanding of peptide biosynthesis and to recent technological advances in molecular biology, we can now better estimate the dynamics of endogenous opioid biosynthesis. In the present studies, we re-examined the question of morphine's effects on brain opioid systems, focusing in particular on the pro-opiomelanocortin (POMC) opioid peptide family.
POMC is the precursor protein of the potent opioid peptide flEl_31 as well as a number of other bioactive peptides, including beta-lipotropin (fi-LPH), adrenocorticotropin (ACTH) and a family of melanocyte-stimulating hormones (MSH's) (see refs. 12, 29 for reviews).
In the CNS, the major POMC cell group is situated in the arcuate nucleus of the medio-basal hypothalamus 7,33,34, with a second, smaller cluster of POMC cell bodies localized in the nucleus of the solitary tract (NTS) and nucleus commissuralis in the cadual medulla 19 projections from the arcuate nucleus innervate a diverse number of brain regions, including various hypothalamic nuclei, the periventricular nucleus of the thalamus, limbic structures such as the septum and amygdala, and the periaqueductal gray (PAG) through the diencephalon and midbrain 17'18'33. Although projection areas of POMC neurons in the NTS have not been well documented, it is possible that the NTS and arcuate groups may share some common terminal fields. While flE1_31 is a major cleavage product of POMC in all tissues, it can undergo further modification by carboxy-terminal cleavage or N-terminal acetylation 2'11'12'37. Thus, full length flE1_31 and the carboxy-terminal shortened forms, flE1_27 and flE1_26 , can exist in N-acetylated or non-acetylated forms. In all brain regions studied, fiE1_31 is the major immunoreactive form of fiE, with smaller amounts of flEl_27 , and no fl-LPH, present 14'35. The great majority of flE-immunoreactive (fiE-k) species in the brain are not acetylated. When the effects of chronic morphine treatment on brain levels of fiE-it were examined in earlier studies, investigators were unaware that at least 7 different peptides (fl-LPH, and N-acetylated or non-acetylated forms of flEl_31, flE1_27 and flE1_26) might be contributing to the total flE-ir detected. It is possible that chronic morphine treatment affects POMC processing in a way which would result in alterations in the concentrations of differently processed flE-ir peptides without changing the total amount of fiE-it. Alterations in the relative amounts of flEl_31 and flEl_27 could be physiologically significant since post-translational modifications of flEx_31 radically alter the opioid characteristics of the peptide. Carboxyterminal shortened forms of flE1_31 are 10 times less potent than flE1_31 in displacing specific opiate binding 4 and fail to produce analgesia 1°. There is also evidence to suggest that flEl_27 is antagonistic to the opiate effects of flEl_315"26. Hence, one question that was addressed in these studies was whether chronic morphine treatment might cause increased processing of flEl_al to flEl_27 , in effect reducing the intracellular concentration of endogenous opioid active material.
While measurements of different immunoreactive forms of fiE are critical for understanding whether POMC processing might be altered following chronic morphine administration, they still represent steady-state concentrations and provide no information about the dynamics of the biosynthetic system (i.e. whether is has been activated or inhibited). The advent of molecular biological techniques which measure small amounts of POMC mRNA allowed us to determine a second parameter of biosynthetic activity. The concomitant measurements of peptide and mRNA levels make it possible to infer information about the dynamics of biosynthetic systems and to more accurately assess whether neural activity has been altered 27. For example, Costa and his colleagues, based upon data showing that levels of POMC mRNA and POMC precursor protein both declined by 30-50% following 5-7 days of morphine pelleting, concluded that chronic morphine causes downregulation of POMC biosynthesis and utilization in the hypothalamus 23'24. It should be noted, however, that not all laboratories have detected changes in POMC mRNA levels following morphine treatment 16 .
Another issue to keep in mind when studying the possible effects of morphine treatment on endogenous opioid systems is that it is likely that cells engage in a series of responses in adapting to changes in their neural activity. An important lesson learned from studies in the pituitary gland (see, for example, ref.
3) is that peptide systems appear to be regulated by several mechanisms which act at different levels of the biosynthetic pathway (e.g., transcription, translation, precursor processing, post-translational modifications) at different times. Thus, it is possible that some parameters of brain POMC biosynthesis may be altered during the early stages of morphine treatment, but these alterations may disappear at later points in the treatment as other regulatory mechanisms become more important. Hence, examining the POMC system at several time points following morphine treatment may be necessary to observe the full sequelae of possible effects of opiate administration on fiE biosynthesis. In this paper, we attempted to provide a description of the effects of chronic morphine administration on the dynamics of brain fiE biosynthesis by measuring different flE-ir peptide species and POMC mRNA levels in a cell body (arcuate nucleus) and nerve terminal (midbrain PAG) brain region at several time points following morphine pellet implantation. Preliminary results of these experiments have been reported 8.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (Charles River Co., Wilmington, MA), weighing 220-250 g at the start of the experiments, were maintained in groups of 5-6 per cage, with free access to food and water, in an environmentally controlled room (12:12 h light:dark cycle, lights on at 06.00 h).
Drug treatments
Animals lightly anesthetized with ether were implanted under the skin between the scapula with morphine (75 mg) or placebo (containing avicel PH-102, magnesium stearate, silicon dioxide, and water) pellets (provided by courtesy of the National Institute of Drug Addiction). In the initial study, animals received a single morphine or placebo pellet on Day 1 and 3 additional pellets on Day 4. On Day 7, morphine-or placebo-pelleted animals were injected i.p. with either naloxone (2.5 mg/kg) or saline vehicle and sacrificed 30 min later. The 4 experimental groups were designated as: Placebo pellets/saline injection (PS); Placebo pellets/naloxone in-jection (PN); Morphine pellets/saline injection (MS); Morphine pellets/naloxone injection (MN). In the time course studies, all animals had one morphine or placebo pellet implanted on Day 1. One set of placebo and morphine animals was sacrificed 24 h later, a second set was killed 72 h after pellet implantation, while a third set of animals was implanted with 3 additional (morphine or placebo) pellets on Day 4 and sacrificed on Day 7. Two brain regions were dissected and frozen immediately on dry ice: (1) a hypothalamic region which contains the major POMC cell body group in the arcuate nucleus as well as a widespread distribution of flE-ir terminals; and (2) a midbrain PAG region rich in flE-ir terminals derived primarily from the arcuate nucleus w'22. The hypothalamus was defined by the optic chiasm, the mammillary nuclei, the lateral aspects of the optic tract, and the top of the third ventricle --wet weight was roughtly 30-40 mg. The midbrain dissection simply involved coronal cuts anterior to the superior colliculi and posterior to the inferior colliculi --wet weight was approximately 115 mg. Total flE-ir was determined in the crude extracts of individual animals. Gel chromatography followed by fiE radioimmunoassay (RIA) was carried out on pooled samples from different experimental groups. POMC mRNA was quantitated by a solution phase-protection assay following extraction of nucleic acids from individual hypothalami.
Gel chromatography
Tissue was homogenized in acetone:0.2 N HCI (3:1) and the supernatant was dried down and resuspended in 1% formic acid containing 0.01% bovine serum albumin (BSA). After aliquots were removed for assay of total fiE-k, pooled extracts of 4-6 animals from each of the treatment groups were subjected to gel filtration chromatography to separate chemicals on the basis of molecular weight. Chromatography was carried out on a 1.5 x 90 cm Sephadex G-50-50 column developed with 1% formic acid containing 0.01% BSA. Fractions (1.3 ml) were collected and vacuum-dried for later assay for flE-ir. The column was precalibrated with blue dextran, cytochrome C, camel fiE 1 31, camel fiE l 27, and cobalt chloride.
Peptide quantitation
flE-ir in tissue extracts and chromatographic fractions was measured by RIA using an antibody directed primarily against the midportion of flEl_31 (i.e. flE17_27 ). At the concentration (1:40,000) used in this assay, and using 125I N-acetyl-flEl_27 as the radiolabelled tracer, the antibody was completely cross-reactive with fl-LPH, flEl_31 , flE1_27 , flEl_26 and their N-acetylated derivatives. The antibody showed no cross-reactivity with other POMC-derived peptides such as flEl_16 , flE1_17, Des-tyrosine flEl_17 , flE27_31 , ACTHI_39, a-MSH or ),-MSH, nor did it cross-react with peptides from other opioid precursors (e.g. Leu-enkephalin, Met-enkephalin, dynorphin A, dynorphin B, a-neo-endorphin). Sensitivity of the assay under equilibrium conditions was 2-3 fmol per tube, with an ICso of approximately 20 fmol. Samples were resuspended in RIA buffer (150 mM Na phosphate buffer with 1% NaCI and 0.1% BSA, pH 8.2) and were quantitated relative to a camel fiE 1 31 standard curve.
POMC mRNA quantitation
POMC mRNA was quantitated in individual hypothalami of animals treated with placebo or morphine pellets for 3 or 7 days using a solution phase hybridization technique modified from Myers et al. 25 . Total nucleic acids were extracted from hypothalami by homogenization in a LET buffer (10 mM Tris-HCl, pH 7.5, 10 mM EDTA, 1% lithium dodecylsulfate). After aliquots were removed for flE-ir determinations, extracts were incubated with 0.1% proteinase K for 60 min at 37 °C and nucleic acids were recovered by phenol/chloroform extractions followed by ethanol precipitation. Radiolabelled antisense cRNA POMC probes were produced by transcribing linearized SP64 or pGEM plasmids containing a mouse or rat POMC cDNA insert, using a-32p-cytosine triphosphate (CTP) as the radioactive label. The hybridization reaction was begun by incubating the radiolabelled cRNA and the extracted nucleic acids in a hybridization buffer (5x hybridization buffer: 0.2 M PIPES, pH 6.4, 2.0 M NaCI, 5.0 mM EDTA) with deionized formamide for 5 min at 90 °C and then for a minimum of 10 h at 50 °C. Single stranded RNA was digested by ribonuclease A (R-5125, Sigma, St. Louis, MO; 10/~g/ml in RNase buffer: 10 mM Tris-HCl, pH 7.5, 5.0 mM EDTA, 0.2 M NaCI, 0.1 M LiCI) at 22 °C for approximately 60 min. RNase activity was destroyed by Proteinase K (40 /~g/ml) treatment in 1% SDS at 37 °C for 30 min. Protected cRNA:mRNA hybrids were extracted with phenol/chloroform followed by ethanol precipitation and were fractionated by electrophoresis on 4% polyacrylamide non-denaturing gels in TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA). The gels were exposed via direct contact autoradiography on Kodak x-Omat XAR5 film and individual bands were quantitated by determining their total integrated optical density using a Loats Image Analysis System (Westminster, MD).
Two different POMC cDNA sequences were used. A mouse cDNA (courtesy of Dr. J. Roberts) contained the coding region for most of CLIP and all of fl-LPH as well as approximately 100 bases of the 3" untranslated region which extended close to the polyadenylation tail site. A rat clone (courtesy of Dr. J. Eberwine) corresponded to the 3" portion of Intron 2 and approximately 365 bases of Exon 3 coding for amino acids 19-139 of the POMC precursor (i.e. ending just past the coding region of ACTHl_39 ). While there is roughly 93% homology between the 440 bases of the mouse riboprobe and the rat mRNA sequence, there are several sites where base mismatches are clustered together (Fig. 1A) . Assuming that the RNase treatment was most likely to nick double-stranded RNA hybrids in regions in which there are non-complementary bases (i.e. in effect making these regions single-stranded), we anticipated that there would be more than one protected band when the mouse cRNA was hybridized against rat POMC mRNA. Since the 3" tail of the mouse probe had several base deletions and additions compared to the rat message, the longest protected hybrid that was predicted was approximately 390 base pairs in length. In addition, we anticipated that protected hybrids corresponding to approximately 240, 210, 160 and 140 base pairs might be observed (Fig. 1A) . There was a fairly good agreement between the predicted sizes of the protected bands (Fig.  1B) and what was actually observed when the protection assay and gel electrophoresis was carried out (Fig. 1C) . The two most intense bands corresponded to hybrids of approximately 350-370 and 240 base pairs in length. In addition, there were fainter bands of roughly 300, 180 and 150 base pairs in size. When the rat riboprobe was hybridized against rat POMC mRNA, only a single hybrid band was observed in autoradiographs of the electrophoresis gels (Fig. 1D ). This band, estimated to be approximately 370 base pairs long, was fully predicted from the hybridization of the portion of riboprobe containing Exon 3 to the complementary region of the mRNA sequence, followed by RNase digestion of the single stranded intronic portion of the probe.
Statistics
Differences between experimental and appropriate control groups were statistically evaluated by 2-tailed t-tests using a significance level of 0.05.
RESULTS
Seven-day morphine~precipitated withdrawal: effects on fl E-ir peptides
In the first experiment, we examined the effect of chronic morphine pelleting on brain fiE-k, focusing in particular on whether the relative concentrations of the different flE-ir species might be altered by this paradigm.
In addition, we were interested in possible changes in flE-ir peptides in morphine-tolerant animals who were undergoing naloxone-precipitated withdrawal. Total fiEir in crude extracts from the hypothalamus and midbrain was approximately the same in the 4 treatment groups ( Fig. 2A,B) . The absence of changes in flE-ir in any of the brain regions examined was reinforced by chromatographic analyses. The chromatographic profiles of flE-ir from the PS, PN, MS and MN groups were extremely similar in both of the brain regions examined (Fig. 3) . In each chromatograph, 3 main peaks of flE-ir were detected, which corresponded to the approximate 
Effect of 7 days of morphine pelleting of POMC peptides in brain
Total flE-ir in the two major peaks observed in the chromatographic profiles of Fig. 3 (Table I) .
Three and seven days morphine treatment: effects on POMC mRNA
In this experiment, we measured the effects of 3 or 7 days of morphine pelleting on POMC mRNA levels in the hypothalamus. POMC mRNA was quantitated in 2 separate studies, using the mouse riboprobe in bands observed in the autoradiographs was densitometrically analyzed (see Fig. 1C ). In every case, the mean optical density of the bands of morphine-treated animals was lower than that of placebo-pelleted controls (although in the cases of Bands 1 and 2, this difference was not statistically significant). Quantitative analysis of the most intense hybrid band (Band 3) indicated that POMC mRNA levels in hypothalami from morphine-treated animals were approximately 50% lower than those seen in placebo-treated controls (t = 4.5, P < 0.01; Fig. 4 ). In Study 2, using the rat POMC cRNA, a single band was protected following RNase digestion (see Fig. 1D ). Densitometric quantitation of this band revealed a small (approximately 20%) decrease in POMC signal in animals morphine-treated for 7 days compared to placebo controls (Fig. 4) , although this difference was not statistically significant. Similar amounts of POMC mRNA were detected in morphine and placebo animals following 3 days of treatment (data not shown).
Morphine time course: effects on flE-ir peptides
Although no changes in flE-ir peptide levels were found following 7 days of morphine treatment, the preceding data, showing that POMC mRNA tends to decline following chronic morphine, suggest the possibility that fie biosynthesis might be reduced in morphinepelleted animals. Hence, we re-examined the effect of morphine pelleting on flE-ir peptide levels at several time points over the 7-day treatment, reasoning that if morphine decreased the release of flE-ir peptides, it might result in an intraneuronal accumulation of flE-ir at some point following morphine administration. flE-ir concentrations in the hypothalami of morphinetreated animals were unchanged from control values following 1 day of pelleting but were significantly increased after 3 days of treatment (Fig. 5A) . Interestingly, flE-ir concentrations after 7 days of morphine treatment were comparable to those found in animals who were morphine-pelleted for 3 days. However, the flE-ir content of placebo controls at 7 days post-pelleting increased relative to 1-or 3-day placebo control levels; hence, as observed previously, no significant treatment effect was detected at this time point. No significant differences between morphine-and placebo-treated animals were observed in midbrain concentrations of flE-ir at any of the time points examined (Fig. 5B) .
When the relative amounts of different sized immunoreactive peptides in the hypothalamus were analyzed, we found that the increase in total hypothalamic flE-ir observed in 3-day morphine-treated animals" appeared to be the result of a selective increase in flE1_27/flEl_26 (Fig.  6A) . The ratio of flE1_31:flEl_27/flE1_26 concentrations in placebo-treated animals (approximately 1:1) declined in morphine-treated animals (to roughly 1:2). In contrast to the hypothalamus, 3 days of morphine pelleting did not alter the relative amounts of fiE1_31 and flEl_ET/flEl_26 found in the midbrain (Fig. 6B) . Following 1 or 7 days of treatment, morphine-and placebo-treated animals displayed similar chromatographic profiles of sieved hypothalamic or midbrain pools (data not shown).
The distribution of flE-ir in the brain following morphine treatment was assessed in a different way by calculating the ratio of the flE-ir content in the hypo- thalamus relative to that found in the midbrain. Following 1 or 7 days of pelleting, there were no differences between the morphine and placebo groups in hypothalamic to midbrain ratios of total flE-ir. However, the hypothalamus:midbrain flE-ir ratio increased from 2:1 in 3-day placebo-treated animals to approximately 6:1 in morphine-pelleted animals. This indicates that morphine caused an apparent redistribution of flE-ir from nerve terminals in the midbrain to POMC cell bodies in the hypothalamus.
DISCUSSION
The main goal of these studies was to determine whether POMC biosynthesis was altered following chronic administration of the opiate agonist, morphine. By examining both peptide and mRNA levels, a more detailed description of the dynamics of POMC biosynthesis was provided compared to earlier reports, when steady-state tissue levels of total flE-ir were the sole measure taken. In agreement with the results of previous studies 6"15"23"24, total fiE+it in selected brain areas (i.e. the hypothalamus and midbrain) was not altered in animals treated for 7 days with morphine pellets or in morphinetreated animals undergoing naloxone-precipitated withdrawal. Furthermore, there does not appear to be any effect of chronic morphine treatment or precipitated withdrawal on the processing of the POMC precursor molecule as evidenced by the fact that the relative amounts of fl-LPH, flEl_31 and flEl_27/flEl_26 remained fairly constant across all treatment groups in the two brain regions examined. The sieving data support recent results showing that 4 days of morphine pelleting had no effect on the processing of flE-ir peptides in the hypothalamus or PAG 6. If one relied solely upon peptide measurements at the 7-day time point, the evidence would suggest that chronic morphine administration had no effect on the biosynthesis of POMC-derived peptides.
When peptide levels were determined at different times over the course of the morphine treatment, an interesting result was observed in placebo-pelleted animals. Hypothalamic concentrations of flE-ir in animals placebo-pelleted for 7 days were approximately twice as high as those found in animals implanted with placebo pellets for 1 or 3 days (see Fig. 5 ). At the present time, it is not known whether the elevated fiE-it concentrations in the 7-day placebo group resulted from increased biosynthesis following increased neural activity or was due to an accumulation of fiE-it subsequent to reduced peptide release. The most obvious explanation for this 'placebo-pelleting' effect relates to differences in the handling of the placebo groups. Animals pelleted for 1 or 3 days were anesthetized and pelleted only once, while those treated for 7 days underwent the pelleting procedure a second time (i.e. on Day 4). The fact that hypothalamic flE-ir increased in the 7-day placebopelleted group relative to the 1-or 3-day groups suggests that some factor(s) associated with the second exposure to the pelleting procedure affected f/E-containing neurons. We are presently investigating whether a second exposure to ether anesthesia alters hypothalamic fiE-ir levels relative to those found in animals anesthetized only once. Although the presence of the 'pelleting' effect precludes making meaningful comparisons about morphine's effects across different time points, valid comparisons between morphine and placebo groups can be evaluated at a given time point.
Keeping in mind the cautionary note just mentioned, we believe that the present studies did yield two pieces of data which lend support to the hypothesis that morphine inhibits fiE biosynthesis in the brain. First, the amount of POMC mRNA detected in animals implanted with morphine pellets for 7 days was reduced (by roughly 50% in Study 1 and 20% in Study 2) compared to placebotreated controls. That we observed a significant effect in one study (using the mouse riboprobe) but not in the other (using the rat POMC cRNA) reflects the confusion that already exists in the literature about whether chronic morphine treatment reduces 23'24 or has no effect 16 on hypothalamic POMC message. The variability in the magnitude of this effect across different studies may indicate that other factors (e.g. stress) have not remained constant in the different studies. In this regard, it is intriguing to note that there have also been conflicting reports on the effects of chronic morphine treatment on pro-enkephalin mRNA levels in the striatum, with some groups reporting that it reduces 32 pro-enkephalin mRNA while others claim it has no effect 24. In future studies, it will be important to either eliminate or control for possible factors which might modulate morphine's effects on endogenous opioid systems. Although variable, the present results, together with earlier data 23'24, suggest that POMC mRNA levels tend to decline following chronic morphine pelleting, indicating that fiE biosynthetic capacity in the hypothalamus might be reduced following 7 days of morphine treatment.
The second piece of evidence which indicates that morphine may inhibit brain POMC biosynthesis and neural activity is that although no changes in tissue content of fiE-ir were observed following 7 days of morphine pelleting, significantly higher levels of fiE-ir were detected in the hypothalami of 3-day morphinepelleted animals compared to 3-day placebo-pelleted controls. While it is conceivable that the accumulation of fiE-it after 3 days of pelleting results from increased POMC biosynthesis, the fact that we observed no increases in POMC mRNA levels, or in any other parameter of fiE biosynthesis or release, argues strongly against this possibility. Our interpretation of these data is that morphine reduced fiE release from POMC neurons while peptide biosynthesis proceeded at a normal rate, causing fiE-ir to gradually accumulate in the hypothalamus. This explanation is supported by the fact that the hypothalamus:midbrain ratio of fiE-ir concentrations was 3-fold greater in morphine-versus placebo-treated animals, suggesting that fiE-ir was no longer being transported to nerve terminals in the midbrain but was accumulating in POMC cell bodies in the hypothalami of morphine-pelleted animals. One could speculate that when morphine treatment was continued beyond 3 days (i.e. to 7 days), homeostatic mechanisms caused POMC mRNA levels to decline to a point where the rate of fiE biosynthesis once again matched the rate of fiE release. Under this new equilibrium between synthesis and release, steady-state peptide levels in tissues of 7-day placebo-and morphine-treated animals would not differ. Also consistent with the notion that the accumulation of hypothalamic fiE-ir after 3 days of morphine is due to inhibited peptide release is the finding that there was a relatively selective accumulation of smaller forms of fiE (i.e. fiEl_26/fiEl_27 ). It is generally believed that peptide processing is a time-dependent process; hence, posttranslational modifications which occur later in the processing pathway (e.g. COOH-terminal cleavage of fiEl_31 , C-terminal amidation, or N-terminal acetylation) may not proceed fully to completion. This appears to be the case for conversion of fiEl_31 tO fiEl_27 and fiEl_26 , as suggested by the fact that this processing event normally occurs less than 50% of the time in the brain and, under some circumstances, can become a rate-limiting biosynthetic step 1. Thus, it seems likely that the accumulation of flEl_27/flE1_E6-ir is indicative of increased storage time in granules (as a result of decreased release), leading to fuller processing. However, other interpretations of how hypothalamic flEl_E7/flEl_26 peptides increase following 3 days of morphine treatment are possible. For example, the enzyme responsible for converting fiE1_31 to fiE1_27 may be transiently activated by morphine treatment.
In addition to altering fiE-ir peptide and POMC mRNA levels at different times during morphine administration, there is some evidence suggesting that morphine may inhibit fiE release in the brain. First, concentrations of fiE-it in the hypophyseal portal plasma, which are thought to reflect release from hypothalamic POMC neurons, declined by over 60% following i.v. administration of morphine and this effect was blocked by naltrexone 2°. Second, results from in vitro studies have shown that the basal and K+-stimulated release of fiE-ir from hypothalamic slices into the incubation media is decreased in tissue of morphine-pelleted animals compared to placebo-pelleted controls (Bronstein and Akil, unpublished observations). These data, while preliminary, suggest that even though fiE-it levels appear to be comparable in morphine-and placebo-treated animals, the peptide pools in morphine-treated animals may be less susceptible to release, or may be differently regulated, than those of control animals.
If it is substantiated that morphine does feedback to inhibit the biosynthesis of an endogenous opioid system, the precise function of the down-regulated system in opiate tolerance and withdrawal would have to be established. The finding that flEl_27/flEl_26 selectively accumulated in the hypothalami after 3 days of morphine treatment could have a profound physiological effect, since flEl_26 and flEl_27 are much less potent peptides than flEl_314'10 The effects of changing the relative amounts of full length and processed flE-ir peptides may not be readily apparent as long as opiate receptors are occupied by morphine. However, once the exogenous opiate is removed, and activation of opiate receptors becomes dependent on endogenous stores of peptides, the decrease in the relative amount offlEl_31 could result in reduced opioid-mediated responses. It is possible that the decreased opioidergic tone in POMC (and perhaps other opioid) neurons which may follow cessation of long-term opiate treatment could play a role in the expression of various withdrawal symptoms.
The present results reveal the importance of measuring several parameters of biosynthetic activity, and sampling at multiple time points, when studying the effects of pharmacological (or other) manipulations on endogenous peptide biosynthesis. If peptide measurements of tissue and sieved extracts were determined at the 7-day time point only, one would most likely conclude that exogenous opiate administration had no effect on POMC biosynthesis. However, by measuring POMC mRNA levels and determining peptide levels at different times during the morphine treatment, we have presented evidence that morphine treatment may inhibit the activity of flE-ir-containing neurons. In future studies, it will be interesting to examine whether these findings will generalize to other morphine administration paradigms.
